Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).

Amin AP, Kennedy KF, Pencina M, Berger P, Piana RN, Lopez J, Kleiman N, Cohen DJ; EVENT Investigators.

Am J Cardiol. 2011 Jun 15;107(12):1751-6. doi: 10.1016/j.amjcard.2011.02.331.

PMID:
21640216
2.

Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.

Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC.

Catheter Cardiovasc Interv. 2010 Oct 1;76(4):513-24. doi: 10.1002/ccd.22546.

PMID:
20882655
3.

Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV Jr, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, Stone GW; Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators.

JACC Cardiovasc Interv. 2008 Dec;1(6):639-48. doi: 10.1016/j.jcin.2008.10.004.

4.

Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.

Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ; REPLACE-2 Investigators.

J Am Coll Cardiol. 2004 Sep 15;44(6):1194-9.

6.

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.

Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schömig A; ISAR-REACT 3 Trial Investigators.

N Engl J Med. 2008 Aug 14;359(7):688-96. doi: 10.1056/NEJMoa0802944. Erratum in: N Engl J Med. 2008 Aug 28;359(9):983.

7.

Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).

White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA.

JACC Cardiovasc Interv. 2015 Mar;8(3):424-433. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18.

8.

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators.

JAMA. 2003 Feb 19;289(7):853-63. Erratum in: JAMA. 2003 Apr 2;289(13):1638.

PMID:
12588269
9.

Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.

Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, Stone GW.

Circ Cardiovasc Interv. 2012 Oct;5(5):705-12. doi: 10.1161/CIRCINTERVENTIONS.112.972869. Epub 2012 Oct 9.

10.
11.

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

Shah A, Feldman DN.

Vasc Health Risk Manag. 2012;8:115-23. doi: 10.2147/VHRM.S23491. Epub 2012 Feb 27. Review.

13.

Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.

Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW; Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators.

Circulation. 2011 Apr 26;123(16):1745-56. doi: 10.1161/CIRCULATIONAHA.110.981688. Epub 2011 Apr 11.

14.

Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.

Lev EI, Kornowski R, Vaknin-Assa H, Brosh D, Fuchs S, Battler A, Assali A.

Am J Cardiol. 2008 Feb 15;101(4):435-9. doi: 10.1016/j.amjcard.2007.09.089. Epub 2007 Dec 20.

PMID:
18312753
15.

Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.

Feldman DN, Wong SC, Gade CL, Gidseg DS, Bergman G, Minutello RM.

Am Heart J. 2007 Oct;154(4):695-701. Epub 2007 Aug 20.

PMID:
17892994
16.

Bivalirudin during primary PCI in acute myocardial infarction.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.

17.

Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.

Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R.

JACC Cardiovasc Interv. 2011 Sep;4(9):1011-9. doi: 10.1016/j.jcin.2011.06.012.

18.

Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial).

Brener SJ, Oldroyd KG, Maehara A, El-Omar M, Witzenbichler B, Xu K, Mehran R, Gibson CM, Stone GW.

Am J Cardiol. 2014 May 1;113(9):1457-60. doi: 10.1016/j.amjcard.2014.02.002. Epub 2014 Feb 12.

PMID:
24630789
19.

Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.

Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL.

Hosp Pract (1995). 2010 Nov;38(4):138-46. doi: 10.3810/hp.2010.11.351.

PMID:
21068538
20.

Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction.

Chu WW, Kuchulakanti PK, Wang B, Torguson R, Clavijo LC, Pichard AD, Suddath WO, Satler LF, Kent KM, Waksman R.

Cardiovasc Revasc Med. 2006 Jul-Sep;7(3):132-5.

PMID:
16945819

Supplemental Content

Support Center